COMMUNIQUÉS West-GlobeNewswire

Medis Celebrates 35th Anniversary
18/11/2024
Marking the company’s 35 years of bringing innovative therapies to patients across Central and Eastern Europe. 18 countries, 400 highly skilled employees, 100 novel medicines, a large assortment of medical products A [...]
Sharps Regains Nasdaq Listing Compliance
18/11/2024
NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe [...]
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18/11/2024
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to [...]
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
18/11/2024
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancer Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib’s clinical development toward [...]
Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024
18/11/2024
RTY-694 increased protein levels and function of ABCB4 and BSEP in primary hepatocytes, two transporters that play a key role in bile composition and bile flow Data demonstrate the potential of PFMs to restore and [...]
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
18/11/2024
Topline results expected in early January 2025 CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of [...]
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
18/11/2024
HOUSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical and nutraceutical [...]
Psychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of Stockholders
18/11/2024
DALLAS, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, reminds its stockholders to vote ahead of the Company’s upcoming annual meeting of stockholders [...]
RESTEM Presents Phase 1 Data of its ULSC Program in Polymyositis/Dermatomyositis at ACR Convergence 2024
18/11/2024
- Oral presentation at ACR highlights safety and efficacy data from the Phase 1 trial of umbilical cord outer lining-derived stem cells (ULSCs) in patients with Polymyositis/Dermatomyositis (PM/DM), an orphan disease [...]
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
16/11/2024
Data presented at the American Heart Association Scientific Sessions show a 67% reduction in bleeding for patients on antiplatelet therapy taking abelacimab as compared to rivaroxaban AZALEA-TIMI 71 is the largest head- [...]
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
16/11/2024
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may [...]
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
16/11/2024
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data from FOREST-HCM Demonstrate Aficamten Durably Reduces the Proportion of [...]
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
16/11/2024
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc analyses of GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac [...]
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
16/11/2024
SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
16/11/2024
Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic response to Lutetium-PSMA Beyond Lutetium-PSMA, these results are relevant to the [...]
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
16/11/2024
MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced today that, on November 13, 2024, the Company received formal notice from [...]
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
15/11/2024
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration
15/11/2024
WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has notified The Nasdaq Stock Market, LLC (“Nasdaq”) of [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
15/11/2024
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]

Pages